Literature DB >> 21941070

Status epilepticus: why, what, and how.

P P Nair1, J Kalita, U K Misra.   

Abstract

Status epilepticus (SE) is an important neurological emergency with high mortality and morbidity. The first official definition of SE was the product of 10 th Marseilles colloquium held in 1962 which was accepted by International League Against Epilepsy in 1964. There are as many types of SE as of seizures. SE is supposed to result from failure of normal mechanisms that terminate an isolated seizure. In half of the cases, there is no history of epilepsy and SE is precipitated by some intercurrent infection. In children, it is often infection, whereas in adults, the major causes are stroke, hypoxia, metabolic derangements, and alcohol intoxication or drug withdrawal. The treatment of SE aims at termination of SE, prevention of seizure recurrence, management of precipitating causes, and the management of complications. The extent of investigations done should be based on the clinical picture and cost benefit analysis. The first line antiepileptic drugs (AED) for SE include benzodiazepines, phenytoin, phosphenytoin, and sodium valproate. Mortality of SE ranges between 7 and 39% and depends on underlying cause and response to AEDs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21941070     DOI: 10.4103/0022-3859.81807

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  15 in total

1.  Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus.

Authors:  Eros Yamel Moreno Morales; Manuel Fernandez Peleteiro; Ernesto Carlo Bondy Peña; Jose Maria Domínguez Lorenzo; Elva Pardellas Santiago; Anxo Fernández
Journal:  Clin Drug Investig       Date:  2015-07       Impact factor: 2.859

2.  Power spectrum analysis and outcomes of non-convulsive status epilepticus: a single-center study.

Authors:  Jianhua Chen; Liri Jin; Xiangqin Zhou; Qiang Lu; Qing Liu; Yan Huang
Journal:  Neurol Sci       Date:  2022-09-30       Impact factor: 3.830

3.  Status epilepticus: Using antioxidant agents as alternative therapies.

Authors:  Liliana Carmona-Aparicio; Cecilia Zavala-Tecuapetla; María Eva González-Trujano; Aristides Iii Sampieri; Hortencia Montesinos-Correa; Leticia Granados-Rojas; Esaú Floriano-Sánchez; Elvia Coballase-Urrutía; Noemí Cárdenas-Rodríguez
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

4.  Status epilepticus: Our experience in a tertiary care centre in Northwestern India.

Authors:  Ashish Bhalla; Biplab Das; Rimi Som; Sandeep Prabhakar; Parampreet S Kharbanda
Journal:  J Emerg Trauma Shock       Date:  2014-01

5.  Serotonin 1A receptor inhibits the status epilepticus induced by lithium-pilocarpine in rats.

Authors:  Yi Yang; Yi Guo; Yifang Kuang; Shan Wang; Yan Jiang; Yao Ding; Shuang Wang; Meiping Ding
Journal:  Neurosci Bull       Date:  2014-01-15       Impact factor: 5.203

6.  Comparison of intranasal and intravenous diazepam on status epilepticus in stroke patients: a retrospective cohort study.

Authors:  Ryota Inokuchi; Naoko Ohashi-Fukuda; Kensuke Nakamura; Tomoki Wada; Masataka Gunshin; Yoichi Kitsuta; Susumu Nakajima; Naoki Yahagi
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

7.  Practice parameters in management of status epileptics.

Authors:  Usha Kant Misra; Jayantee Kalita; Sanjeev Kumar Bhoi
Journal:  Ann Indian Acad Neurol       Date:  2014-03       Impact factor: 1.383

8.  Clinical predictors of seizure recurrence after the first post-ischemic stroke seizure.

Authors:  Hyeon Jin Kim; Kee Duk Park; Kyoung-Gyu Choi; Hyang Woon Lee
Journal:  BMC Neurol       Date:  2016-11-05       Impact factor: 2.474

Review 9.  The Need for Antiepileptic Drug Chronotherapy to Treat Selected Childhood Epilepsy Syndromes and Avert the Harmful Consequences of Drug Resistance.

Authors:  Sheryl Manganaro; Tobias Loddenkemper; Alexander Rotenberg
Journal:  J Cent Nerv Syst Dis       Date:  2017-12-20

Review 10.  Alcohol withdrawal syndrome: mechanisms, manifestations, and management.

Authors:  S Jesse; G Bråthen; M Ferrara; M Keindl; E Ben-Menachem; R Tanasescu; E Brodtkorb; M Hillbom; M A Leone; A C Ludolph
Journal:  Acta Neurol Scand       Date:  2016-09-01       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.